Pyrimido(5,4-e)-1,2,4-triazine-5,7(1H,6H)-dione, 1,6-dimethyl-3-((Z)-2-phenylethenyl)- | 32502-17-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Pyrimido(5,4-e)-1,2,4-triazine-5,7(1H,6H)-dione, 1,6-dimethyl-3-((Z)-2-phenylethenyl)-
• 英文别名: 1,6-dimethyl-3-[(Z)-2-phenylethenyl]pyrimido[5,4-e][1,2,4]triazine-5,7-dione
• CAS: 32502-17-3
• 化学式: C₁₅H₁₃N₅O₂
• 分子量: 295.3
• InChiKey: DKCTYPSLDALVIU-HJWRWDBZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  77.7
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Inhibitors of HIV-1 integrase multimerization
  申请人：Institute for Cancer Research

  公开号：US10888564B2

  公开（公告）日：2021-01-12

  The disclosure generally relates to compounds of formulas (I) and (II)7 including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV-1 integrase, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

  本公开一般涉及式(I)和(II)7化合物，包括治疗人类免疫缺陷病毒（HIV）感染的组合物和方法。本公开提供了 HIV-1 整合酶的新型抑制剂、含有此类化合物的药物组合物以及使用这些化合物治疗 HIV 感染的方法。
• INHIBITORS OF HIV-1 INTEGRASE MULTIMERIZATION
  申请人：Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center

  公开号：US20210113570A1

  公开（公告）日：2021-04-22

  The disclosure generally relates to compounds, compositions, and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV-1 integrase, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
• [EN] INHIBITORS OF HIV-1 INTEGRASE MULTIMERIZATION<br/>[FR] INHIBITEURS DE LA MULTIMÉRISATION DE L'INTÉGRASE DU VIH -1
  申请人：INSTITUTE FOR CANCER RES D B A THE RES INSTITUTE OF FOX CHASE CANCER CENTER

  公开号：WO2018140762A1

  公开（公告）日：2018-08-02

  The disclosure generally relates to compounds of formulas (I) and (ll)7 including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV-1 integrase, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.